Document is current
Any future updates will be listed below
-
Authors
Curik, Nikola
Laznicka, Adam
Krizkova, Jitka
Suchankova, Pavla https://orcid.org/0000-0002-2611-5848
Vavrova, Adela https://orcid.org/0009-0006-5848-8573
Polivkova, Vaclava
Pokorna, Eva
Semerak, Pavel
Burda, Pavel https://orcid.org/0000-0002-2841-792X
Kuzilkova, Daniela https://orcid.org/0000-0001-8086-9790
Kalina, Tomas https://orcid.org/0000-0003-4475-2872
Hochhaus, Andreas https://orcid.org/0000-0003-0626-0834
Machova Polakova, Katerina https://orcid.org/0000-0002-7398-5555
-
Funding
Funding for this research was provided by:
Novartis
- License Information
-
More Information
Article History
Received: 11 May 2025
Revised: 2 July 2025
Accepted: 4 August 2025
First Online: 26 August 2025
Competing interests
: KMP and AH received support by Novartis through the European Treatment and Outcome Study (EUTOS) for CML.
: All methods and procedures were performed in accordance with the relevant guidelines and regulations. All animal-related procedures and the experimental design were reviewed and approved by the Institutional Animal Care and Use Committee and Ministry of Education, Youth and Sports of the Czech Republic (approval number MSMT-5374/2024-4).
